Heartsciences INC

HeartSciences Inc. received a notice from Nasdaq for failing to meet minimum stockholders' equity requirements, with a proposed merger cited as a potential solution to regain compliance.

HeartSciences Inc. announced its preliminary proxy statement filing for a business combination with Fortitude Mining Holdings, Inc., alongside its fiscal 2026 financial results and business updates.

HeartSciences Inc. has filed an 8-K/A to supplement its prior 8-K filing regarding the merger agreement with Fortitude Mining Holdings, Inc., providing necessary financial statements and pro forma information.

HeartSciences Inc. has entered into Amendment No. 1 to its Agreement and Plan of Merger with Fortitude Mining Holdings, Inc., modifying key terms related to LLC agreements and shareholder action.

HeartSciences Inc. announced the filing of its fiscal 2026 Form 10-K and anticipates filing a preliminary proxy statement for its proposed merger with Fortitude Mining Holdings, Inc.

HeartSciences Inc. announced an amendment to its CFO's employment agreement and a grant of restricted stock units, both effective July 7, 2026, tied to a pending merger.

HeartSciences Inc. reports progress on its AI-ECG platforms, secures significant financing, and addresses going concern issues in its Q3 2026 filing.

HeartSciences Inc. reported minimal revenue growth and continued net losses in its Q2 2026 filing, while advancing its AI-ECG technology and securing significant capital through equity offerings.

HeartSciences Inc. reports increased cash and equity from recent capital raises, advancing its AI-ECG technology and FDA submissions despite ongoing net losses and going concern doubts.

HeartSciences Inc. reports its Q3 2025 results, highlighting ongoing efforts to obtain FDA clearance for its MyoVista wav ECG device and addressing concerns about its ability to continue as a going concern.

HeartSciences Inc. released its second quarter 2025 results, highlighting ongoing efforts towards FDA submission for its MyoVista wav ECG device and the development of AI-ECG algorithms.

Heart Test Laboratories reports a net loss of $2.1 million for the third quarter of 2024, while progressing towards FDA submission for its MyoVista wav ECG device.

HeartSciences Inc. filed its annual report for fiscal year 2026, detailing its ongoing development of AI-ECG technology and a proposed merger with Fortitude.

HeartSciences Inc. reported a significant increase in net losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, while actively pursuing FDA clearances for its AI-ECG devices and addressing Nasdaq listing requirements.

Heart Test Laboratories' 10-K filing details its financial status, ongoing development of AI-ECG technology, and plans for FDA submissions.

HeartSciences Inc. reports the grant of 25,000 restricted stock units to Chief Financial Officer Danielle Watson, contingent on a merger closing and continued employment.

Andrew Simpson, Director and CEO of HeartSciences Inc., received a grant of 425,000 shares of common stock as a retention bonus tied to a merger agreement.

HeartSciences Inc. director David R. Wells was granted 15,000 Restricted Stock Units, subject to shareholder approval and performance-based vesting conditions.

HeartSciences Inc. Director Bruce Bent received a grant of 15,000 Restricted Stock Units, subject to vesting conditions including shareholder approval, time-based milestones, and performance targets.

HeartSciences Inc. Chief Operating Officer Mark T. Hilz was granted 45,000 Restricted Stock Units, vesting over three years with performance and change of control accelerators.

HeartSciences Inc. Director Brian Szymczak was granted 15,000 Restricted Stock Units, subject to specific vesting conditions including shareholder approval and performance targets.

HeartSciences Inc. announces its 2026 Annual Meeting of Shareholders to address director election, an expanded equity incentive plan, officer liability exculpation, and auditor ratification.

Heart Test Laboratories has filed a definitive proxy statement with the SEC.

Heart Test Laboratories, Inc. announces its Annual Meeting of Shareholders to be held virtually on November 7, 2024, seeking shareholder approval on key proposals including the ratification of its independent accounting firm.

Heart Test Laboratories aims to raise capital through a new stock and warrant offering to fund FDA clearance efforts and commercial development of its AI-ECG technology.

Heart Test Laboratories is registering the resale of up to 34,684,859 shares of its common stock by selling stockholders, including shares issued to Mount Sinai, Lincoln Park Capital, John Q. Adams, and Matthews Southwest Holdings.

Investor Ephraim Fields has filed a Schedule 13G reporting an 8.1% beneficial ownership stake in HeartSciences Inc.